Servier gets rights to Galapagos' OA candidate

In July, Servier (Neuilly-sur-Seine, France) said it exercised its option for worldwide commercialization rights, excluding the U.S., to GLPG1972 (S201086) from Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG). Galapagos retains U.S. commercialization rights.

Galapagos will receive a €6 million ($7 million) license fee and is eligible for up to €290 million ($340.5 million) in milestones, plus royalties outside the U.S. The inhibitor of ADAM metallopeptidase with thrombospondin type 1 motif 5 (ADAMTS5) is in Phase Ib testing to treat osteoarthritis (OA)...